Literature DB >> 23385694

Chronic insomnia.

David N Neubauer1.   

Abstract

PURPOSE OF REVIEW: This article provides an overview of current strategies for evaluating and treating patients who experience chronic insomnia. RECENT
FINDINGS: The US Food and Drug Administration (FDA) has approved several medications for the treatment of insomnia that incorporate a variety of pharmacodynamic and pharmacokinetic properties, thus allowing the development of a customized therapeutic approach. FDA-approved medications include γ-aminobutyric acid-modulating benzodiazepine receptor agonists, a melatonin receptor agonist, and a histamine receptor agonist. Psychological and behavioral techniques combined as cognitive-behavioral therapy also have been shown to be effective in the treatment of chronic insomnia.
SUMMARY: Insomnia is the most common sleep disturbance and represents a chronic condition for many people. Difficulty falling asleep and maintaining sleep are highly prevalent problems in patients with neurologic disorders. Multiple factors typically contribute to insomnia. Accordingly, a rather broad approach to evaluating patients is warranted. Evidence-based guidelines support the use of cognitive and behavioral strategies and selected medications in the treatment of patients with chronic insomnia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23385694     DOI: 10.1212/01.CON.0000427213.00092.c1

Source DB:  PubMed          Journal:  Continuum (Minneap Minn)        ISSN: 1080-2371


  4 in total

1.  Sleep quality of Shanghai residents: population-based cross-sectional study.

Authors:  Wenjun Wu; Yonggen Jiang; Na Wang; Meiying Zhu; Xing Liu; Feng Jiang; Genming Zhao; Qi Zhao
Journal:  Qual Life Res       Date:  2019-11-28       Impact factor: 4.147

2.  Strategies of Functional Foods Promote Sleep in Human Being.

Authors:  Yawen Zeng; Jiazhen Yang; Juan Du; Xiaoying Pu; Xiaomen Yang; Shuming Yang; Tao Yang
Journal:  Curr Signal Transduct Ther       Date:  2014-12

3.  Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence.

Authors:  Yuan Shi; Jing-Wen Dong; Jiang-He Zhao; Li-Na Tang; Jian-Jun Zhang
Journal:  Curr Neuropharmacol       Date:  2014-05       Impact factor: 7.363

Review 4.  Clinical management of sleep disturbances in Alzheimer's disease: current and emerging strategies.

Authors:  Elena Urrestarazu; Jorge Iriarte
Journal:  Nat Sci Sleep       Date:  2016-01-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.